Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

NCT ID: NCT01474161

Last Updated: 2012-11-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 96 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-11-30
• Study Completion Date: 2012-11-30

Brief Summary

The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation (capsule dosed at 20 mg GFT505) in healthy male subjects and to assess the impact of gender on this relative bioavailability after administration in male and female subjects.

Using the new formulation, a single and a multiple ascending dose study will be performed in overweight or obese male subjects otherwise healthy whose demographic and physiological characteristics are thought to be closer to those of the target population (Type 2 diabetes). Thereafter, a group of male and female patients with Type 2 diabetes will receive multiple dose administration of GFT505.

Detailed Description

The study will be divided in 4 successive parts :

• Study Part I will be a comparative bioavailability between a new GFT505 formulation (capsule dosed at 60 mg GFT505 by capsule) and the old GFT505 formulation (capsule dosed at 20 mg GFT505 by capsule) coupled with an evaluation of the gender effect assessed with the new formulation. In this purpose a group of 12 male subjects will receive successively both formulations on a unique occasion in a randomized manner while a group of 12 female subjects will receive the new formulation on one occasion only. This part of the study will be done in healthy volunteers.
• Study Part II will be a single ascending dose to be run at a maximum of 3 dose levels. Subjects included in this part of the study will receive only one dose level to limit the exposure to GFT505. Three cohorts of 8 subjects are planned to be included. This part will be run in overweight or obese subjects.
• Study Part III will start after completion of the first Cohort of Study Part II. Study Part III will be a multiple ascending dose to be run at a maximum of 3 dose levels. Subjects included in this part of the study will receive only one dose level to limit the exposure to GFT505. Three cohorts of 12 subjects are planned to be included. This part will be run in overweight or obese subjects.
• Study Part IV will follow the same design and same treatment schedule than Study Part III but will be performed in the target population, patients with Type 2 diabetes and only one dose will be tested in study part IV.

Conditions

Type 2 Diabetes; Diabetes Mellitus, Type 2; Metabolic Diseases; Cardiovascular Diseases; Obese; Dyslipidemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Matching placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).

GFT505 20mg - old formulation

Study Part I : dose level = 120mg

Group Type: ACTIVE_COMPARATOR

GFT505 120mg - old formulation

Intervention Type: DRUG

hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.

GFT505 60mg - new formulation

Study Part I : dose level = 120mg ; Study Part II : dose level = 180mg, 240mg and 300mg ; Study Part III : dose level = 120mg, 180mg and 240mg ; Study Part IV : dose level = 120mg or 180mg.

Group Type: EXPERIMENTAL

GFT505 120mg - new formulation

Intervention Type: DRUG

hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.

GFT505 180mg - new formulation

Intervention Type: DRUG

hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.

GFT505 240mg - new formulation

Intervention Type: DRUG

hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.

GFT505 300mg - new formulation

Intervention Type: DRUG

hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.

Interventions

GFT505 120mg - old formulation

hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.

Intervention Type: DRUG

GFT505 120mg - new formulation

hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.

Intervention Type: DRUG

GFT505 180mg - new formulation

hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.

Intervention Type: DRUG

GFT505 240mg - new formulation

hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.

Intervention Type: DRUG

GFT505 300mg - new formulation

hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.

Intervention Type: DRUG

Placebo

hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Part I :

• Male or female healthy volunteers 18 to 45 years of age (inclusive).
• Subjects with a body mass index (BMI) ≥ 18 and ≤ 28 kg/m2 at screening.
• For female subjects of childbearing potential, use of double contraception method.
• Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not clinically significant by the principal Investigator.

Part II and III :

• Male healthy volunteers 18 to 55 years of age (inclusive).
• Subjects with a BMI >28 and <35 kg/m2 at screening.
• Normal arterial BP and pulse rate or, if abnormal, considered not clinically significant by the principal Investigator.

Part IV :

• Male or female Type 2 diabetic patients 18 to 60 years of age.
• Females participating in the study must be either of non-child bearing potential or using an efficient double contraception.
• Currently treated with any antidiabetic treatment (a maximum of two anti-diabetic drugs including metformin in all cases) with the exception of insulin or GLP analogs and agonists therapy.
• Stable diabetes with glycosylated hemoglobin (HbA1c) < or =10% or less.
• Normal renal function as defined by a creatine clearance >90 mL/min calculated with the Cockcroft-Gault formula.
• Subjects with a BMI from 18 to 32 kg/m2 at screening.

Exclusion Criteria

Part I :

• Who previously received GFT505.
• With any clinically significant abnormality following review of prestudy laboratory tests (Aspartate and Alanine aminotransferase must be within normal ranges), vital signs, full physical examination and Electrocardiogram.
• Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or anti-HIV 1/2 (Human immunodeficiency virus) or anti-HCV (Hepatitis C virus) antibodies.
• Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per week, one unit = 8 g or about 10 mL of pure alcohol).
• Who drink more than 8 cups daily of beverage containing caffeine.
• Who have a positive laboratory test for urine drug screening (opiates, cocaine, amphetamine, cannabis, benzodiazepines).
• Who have undergone surgery or have donated blood within 12 weeks prior to the start of the study.
• Who have taken any prescribed or over the counter drug (including antacid drug), with the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first dose administration.

• Who have taken fibrates within 6 weeks prior to the first dose administration.

• With unstable proliferative retinopathy, macular oedema (fundus examination performed in the previous year will be considered relevant on Investigator's judgement).
• Who have taken fibrates within 6 weeks prior to the first dose administration.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

SGS Aster S.A.S.

UNKNOWN

Sponsor Role: collaborator

Naturalpha

INDUSTRY

Sponsor Role: collaborator

Genfit

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rémy Hanf, Development Director

Role: STUDY_DIRECTOR

GENFIT, France

Philippe Betting, MD

Role: PRINCIPAL_INVESTIGATOR

SGS Aster S.A.S., Phase I Clinical Unit, France

Locations

SGS Aster S.A.S. - Phase I Clinical Unit

Paris, , France

Countries

France

Other Identifiers

2011-004723-13

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

GFT505-111-7

Identifier Type: -

Identifier Source: org_study_id